The Optimal Treatment for Treatment-resistant Schizophrenia

The Optimal Treatment for Treatment-resistant Schizophrenia

The Optimal Treatment for Treatment-resistant Schizophrenia

To explore the curative effect and safety of Risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.

Inclusion Criteria:

• The diagnosis of schizophrenia according to DSM-V
• 18～60 years old
• 2 prior failed treatment trials with 2 different antipsychotics at doses of at least 600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration;
• Signed an informed consent

Exclusion Criteria:

• patients to be diagnosed according to DSM-V for substance abused, development delayed
• suffering from serious physical disease and can not accept the treatment
• MST contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure
• allergic to risperidone ,aripiprazole, or sodium valproate
• Participated in any clinical subject within 30 days
• Pregnancy or lactation